Study on Pimavanserin for Alzheimer’s Disease Psychosis

Overview of Alzheimer’s Disease Psychosis

A recent study examined the potential of pimavanserin, a medication used for Parkinson’s disease psychosis, in treating psychosis associated with Alzheimer’s disease. Approximately 45 million individuals globally are affected by Alzheimer’s disease, with 25-50% experiencing psychotic symptoms such as hallucinations and delusions at some point. Psychosis impairs an individual’s ability to differentiate between reality and illusion, and if left untreated, symptoms can fluctuate in severity, significantly impacting both patients and caregivers.

Current Treatment Options

Psychosis in Alzheimer’s disease is an independent predictor of accelerated cognitive decline, which correlates with increased caregiver burden, early institutionalization, and higher treatment-related mortality rates. Currently, many patients are prescribed antipsychotics, as no specific drug is approved for treating psychosis in Alzheimer’s patients. However, studies indicate that antipsychotics show minimal efficacy compared to placebo in this population.

Research Methodology

Trial Design

Researchers from the United Kingdom and the United States conducted a randomized, double-blind, placebo-controlled phase 2 trial to evaluate the effectiveness of pimavanserin in Alzheimer’s patients experiencing psychosis. Pimavanserin is an FDA-approved antipsychotic for Parkinson’s disease psychosis. The findings were published in The Lancet Neurology.

Participants and Treatment

The trial involved 178 participants aged 50 and older, suspected of having Alzheimer’s disease along with psychotic symptoms, from 133 nursing homes in Greater London and southern England. Participants were randomly assigned to receive either pimavanserin or a placebo for 12 weeks. The study aimed to assess efficacy, tolerability, safety, and any sustained benefits of pimavanserin compared to placebo.

Assessment Methods

Participants were evaluated for changes in psychosis scores using the Mini-Mental State Examination and the Neuropsychiatric Inventory-Nursing Home version, assessed at baseline, six weeks, and 12 weeks. Previous research indicates that a six-week treatment period is adequate for evaluating treatment efficacy in neurodegenerative diseases.

Findings

Short-Term Results

After six weeks, those receiving pimavanserin exhibited a significant reduction in psychosis scores, nearly double the improvement compared to the placebo group. However, by the 12-week mark, this improvement was not sustained, and no significant differences were noted between the two groups.

Researcher Observations

The researchers acknowledged the limited sensitivity in measuring cognitive function over 12 weeks, advising caution in interpreting these results. The evidence suggests that pimavanserin does not offer a substantial advantage over placebo for Alzheimer’s patients. Importantly, no adverse effects on cognitive or motor functions were observed in either group, and the safety profile aligned with prior studies involving Parkinson’s patients treated with pimavanserin.

Conclusion and Future Directions

Need for Further Research

Given the short-term efficacy of pimavanserin in treating psychosis without negative impacts on cognition or function, further investigation is necessary. The researchers advocate for a large randomized controlled phase-3 clinical trial to explore long-term efficacy, safety, and tolerability in Alzheimer’s patients, as well as to identify the optimal target demographic for treatment.

Reference

Ballard C, Banister C, Khan Z, Cummings J, Demos G, Coate B, Youakim JM, Owen R, Stankovic S; ADP Investigators. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol. 2018 Mar;17(3):213-222. doi: 10.1016/S1474-4422(18)30039-5.